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ABSTRACT
Objective To determine if a laboratory data report
(the HbA1c Tracking Tool) could be used as an
eﬀective intervention to improve diabetes manage-
ment.
Design A longitudinal quasi-experimental cohort
designwas used to test the eﬀectiveness of anHbA1c
summary report sent to primary care physicians for
all patients having HbA1c levels greater than 7%.
Setting Moncton, New Brunswick, Canada.
Sample selection Administrative data from all
adult patients with diabetes who had had at least
two HbA1c measurements within the year prior to
the initiation of the HbA1c Tracking Tool, and who
had had ﬁve years of HbA1c measurements (2002–
2007) overall was included.
Interventions In March 2006 all primary care
physicians began receiving HbA1c summary reports
(through the HbA1c Tracking Tool) as a means to
improving the management of diabetes.
Main outcome measures (a) patient glycaemic
control as indicated by HbA1c levels, (b) physician
adherence to practice guidelines as indicated by
measuring the mean number of HbA1c tests ordered
per patient per year, and (c) physician usage rates of
the HbA1c Tracking Tool in clinical practice.
Results The sample (n=955)was divided into three
subgroups based on ﬂagged HbA1c level (7–<8%,
8–9%, >9%). The strongest eﬀect of the interven-
tion was found in the two groups with the poorest
glycaemic control. The eﬀect was stronger in the
>9% group (from 10.1 to 9.3%), than in the 8–9%
group (a drop of 8.5 to 8.3%). Longitudinal ana-
lyses over a ﬁve-year period indicated the same
ﬁndings. Patients were also found to receive more
tests across time (from 2.45 tests per year to 3.0
across ﬁve years). In terms of usage, 92.1% of the
physicians surveyed used the tool in their practice.
Conclusion Routinely collected hospital laboratory
data can be used both as the basis for an infor-
mation-based intervention and as a tool tomonitor
quality of diabetes care.
Keywords: computerised medical records system,
diabetes mellitus, glycosylated haemoglobin
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Introduction
The prevalence of diabetes in Canada is increasing at
an alarming rate and primary care physicians play a
key role in the care of patients with diabetes. The
Canadian National Physician Survey (2007)1 found
that 88.7%of primary care physicians care for patients
with diabetes. According to the Public Health Agency
of Canada and the Canadian Diabetes Association,
over two and a quarter million Canadians have dia-
betes, and more than 60 000 new cases are diagnosed
each year.2 Population-based studies have estimated
the true prevalence of diabetes in Canada may be
>7%.3–5
Over 40% of Canadians with diabetes are expected
to develop long-term complications as a result of
diabetes, such as stroke, myocardial infarctions, neph-
ropathy, and peripheral vascular disease.2 However, a
number of investigations have shown that optimal
glycaemic control can reduce the incidence of micro-
vascular complications in both type 1 and type 2
diabetes.6–8 Current clinical practice guidelines target
haemoglobin HbA1c level >7% for patients with type
1 and 2 diabetes and recommend monitoring HbA1c
levels every three months until optimal control is
achieved.9 Not only does HbA1c measurement serve
as an intermediate health outcome in clinical settings,
but it can also be used as an evidence-based perform-
ance measure to assess the quality of diabetes care.10
A number of strategies to improve primary care
management of diabetes have been developed and such
initiatives as clinical resource nurses, diabetes education
centres, and oﬃce recall systems have been shown to
enhance the management of patients with diabetes. A
recent Cochrane Review11 showed that organisational
interventions that enhanced structured recall and review
of patients also improved diabetes management. These
ﬁndings show that electronic health records can play a
vital role in improving healthcare quality. Computer-
generated paper reminder systems have also been
found to increase rates of cancer screening and adult
immunisations.12–14
The purpose of the present study was to determine
if a laboratory data report (the HbA1c Tracking Tool)
could be used as an eﬀective intervention to improve
primary care management of diabetes mellitus patients.
Three indicators were used to measure the eﬀective-
ness of the intervention: (a) patient glycaemic control
as indicated by HbA1c levels, (b) physician adherence
to clinical practice guidelines as indicated by meas-
uring the mean number of HbA1c tests ordered per
patient per year, and (c) usage rates of the HbA1c
Tracking Tool by primary care physicians.
Method
Design
Data for this study were obtained from two sources.
First, administrative data were used to access infor-
mation about patients’ HbA1c levels and adherence to
practice guidelines. HbA1c levels for all patients with
diabetes aremeasured by themedical laboratory services
at the Moncton Hospital using the High Performance
LiquidChromatography technique and results are stored
within the South-east Regional Health Authority of
New Brunswick (SERHA) Laboratory Information Sys-
tem. In March 2006, all primary care physicians began
receiving HbA1c summary reports for 1997 to the
present for all patients having HbA1c levels greater
than 7%. These HbA1c tracking reports were printed
on ﬂuorescent paper. Subsequent to a three-month
intervention period initiation, data from these reports
were entered into an SPSS (V15) database. Variables
included current and previous HbA1c levels, age, sex
and the patient’s primary care physician. The number
of HbA1c tests taken by each of these patients per year
was also determined from the laboratory data.
Second, all primary care physicians at SERHA in
2006 were invited to participate in a short survey
asking about their use of the HbA1c Tracking Tool
and for demographic information about the phys-
icians.
Setting
SERHA serves a population of approximately 180 000
people, which includes patients from urban (57%)
and rural (43%) communities within the province of
NewBrunswick. SERHA is serviced by 78 primary care
physicians.15 This study was granted ethics approval
by the SERHA Research Ethics Board.
Selection of participants
All patients older than 18 years of age with diabetes
(type 1 and type 2) with at least two HbA1c measure-
ments within the year prior to the initiation of the
HbA1c Tracking Tool, and with ﬁve years of HbA1c
measurements (2002–2007) were included in the study.
Prospective HbA1c levels were added to the database
for 12 to 15 months after the introduction of the
Tracking Tool. All primary care physicians servicing
SERHA received a survey.
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Analysis
The samplewas divided into three subgroups based on
HbA1c level at study initiation (7–<8%, 8–9%, >9%).
Similar groups had been used in previous studies.16
Descriptive analyses were carried out for both patients
and physicians. For the ﬁrst and second measures
(HbA1c levels and number of HbA1c tests per patient
per year), two mixed analyses of variance (ANOVAs)
were used. The mixed ANOVA allows a test of both a
between-groups factor (i.e. HbA1c subgroups) and a
repeated-measures factor (i.e. a comparison of the
same individuals the year before and the year after the
intervention of the Tracking Tool) in the same stat-
istical test. Repeated measures with trend analyses were
performed to track changes across ﬁve years. These
analyses test whether the change across time is best
represented by a linear trend (i.e. a straight line), a
quadratic trend (i.e. a U-shaped curve), or a cubic trend
(i.e. where the direction of change shifts twice). Finally,
the percentage of physicians surveyedusing theTracking
Tool in their practice was calculated. For all analyses, a
signiﬁcance criterion of p<0.05 was used.
Results
During the project study period 2302 patients received
HbA1c tests. After applying the study inclusion cri-
teria, 955 patients were available for analysis. Overall
56% of patients were in the 7–<8% category, 28.2%
were in the 8–9% category and 15.8% of patients were
in the >9% category group (see Table 1).
A one-way analysis of variance showed that the
three groups diﬀered on age, F(2952) = 20.1, p<0.001,
Z2 = 0.04, with Tukey’s HSD post hoc tests showing
that patients with higher HbA1c levels were younger.
A chi-squared test conﬁrmed that groups did not
diﬀer signiﬁcantly on gender (2(df = 2) = 1.98, p =
0.37).
The response rate for the physician survey was
49.4% (38 out of 77), with 19 males and 19 females.
The majority of physicians were between 40 and 59
years of age (52%); 10 (26.3%) had been practising for
less than ﬁve years, 14 (36.8%) had been practising for
more than 20 years and the rest had been in practice
for between ﬁve and 20 years.
Glycaemic control
To investigate the eﬀect of the introduction of the
HbA1c Tracking Tool across the threeHbA1c categories
of patients, a 2 (one year before/one year after tracking
tool) x 3 (HbA1c patient categories) mixed ANOVA
was carried out. For the 7–<8% group, the average
HbA1c score was slightly higher ((M = 7.7, SD = 0.60)
after the intervention than before (M =7.5, SD = 0.3),
F (1533) = 128.9, p<0.001, Z2 = 0.20). For the 8–9%
group, the average HbA1c score was slightly lower (M
= 8.3, SD = 0.84) after than intervention than before
((M = 8.5, SD = 0.3), F (1269) = 13.7, p<0.001, Z2 =
0.05). Finally, for the >9% group the average HbA1c
was lower after the intervention (M = 9.3, SD = 1.3)
than before ((M = 10.1, SD = 0.95), F (1150) = 54.65,
p>0.001, Z2 = 0.27). Results did not diﬀer when
adjusted for age.
As a follow-up to this ﬁnding, separate repeated-
measures ANOVAs were used to track mean HbA1c
trends across the entire ﬁve-year period. These data
are presented in Figure 1. For the >9% group, means
steadily increased over the ﬁrst four years and then
decreased after the Tracking Tool was introduced
(namely, a quadratic trend: F (1150) = 44.9, p<0.001,
Z2 = 0.23). For the 8–9% group, only slight variations
occurred (fourth order trend: F(1269) = 24.04, p<0.001,
Table 1 Study descriptive statistics by HbA1c category
Variable HbA1c category
7–<8% 8–9 >9% Total
Number 534 270 151 955
Mean age
( SD*)
64.0
(12.6)
60.4
(13.8)
56.8
(14.2)
61.8
(13.4)
Patient sex (%)
Male 308 (57.7) 149 (55.2) 94 (62.3) 551 (57.7)
Female 226 (42.3) 121 (44.8) 57 (37.7) 404 (42.3)
* SD = standard deviation
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Z2 = 0.02). For the 7–<8% group, similar small vari-
ations occurred from year to year (namely, a cubic
trend: F (1533) = 89.01, p<0.001, Z2 = 0.14).
Practice guidelines: number of HbA1c
tests
Patients received more HbA1c tests per year after the
intervention (M= 3.0, SD = 0.91) than the year before
((M = 2.7, SD = 1.0), F (1954) = 51.7, p<0.001, Z2 =
0.05).
Results from a repeated measures analysis across a
ﬁve-year period showed that patients received signiﬁ-
cantly more tests across time (F(43816) = 67.3, p<0.001,
Z2 = 0.07). From 2002 to 2007 the mean number of
tests taken was 2.45, 2.55, 2.54, 2.74 and 3.0 respect-
ively. When numbers of tests per year were compared
for each year pair, the eﬀect sizes were as follows:Z2 =
0.01, < 0.001, 0.03, 0.05. The largest eﬀect size thus
occurred when comparing the year before with the
year after the intervention.
Usage rates
With regards to the utilisation of the HbA1c Tracking
Tool, 35 (92.1%) of the 38 physicians surveyed used
the HbA1c Tracking Tool to monitor patients’ HbA1c
levels. Twenty-seven (71.1%) showed theHbA1c Track-
ing Tool to patients, while eight (21.1%) gave patients
a copy of the HbA1c Tracking Tool. Of the 38 primary
care physicians surveyed, only two (5.3%) did not use
the HbA1c Tracking Tool at all.
Discussion
This project demonstrated that an organisational
intervention that relies on existing and routinely avail-
able data shows an associationwith primary care diabetes
management. The strongest association between the
intervention and diabetes management was found in
the group with the poorest glycaemic control, i.e.
individuals with HbA1c levels over 9%. Although these
high-risk patients have been found to improve gradu-
ally over time under standard diabetes management
care,16 the pre–post intervention comparison observed
herewasparticularly dramatic. Physiciansmayusemore
aggressive therapeutic strategies when lack of glycaemic
control is highlighted by the tracking tool. We also
found that the number of HbA1c tests carried out was
increasing over time. It may be that the tracking tool
made physicians aware of the need to request frequent
HbA1c testing because even though testing rates have
improved steadily over the past ﬁve years, the increase
was particularly strong in the year following the inter-
vention. These results reﬂect better adherence to the
Canadian Diabetes Association Clinical Practice Guide-
lines,9 which recommends HbA1c testing every three
months. Increased testing may lead to more frequent
patient visits to physicians and better continuity of care.
The tracking tool developed for the present study
was designed to be user friendly and easily interpreted.
Indeed,most physicians showed it to their patients and it
may be that the success of the intervention hinged on
patients seeing their own HbA1c levels across time,
and thereby taking a more active role in their own
care. More patient involvement in combination with
Figure 1 Marginal mean HbA1c level by HbA1c category for diabetic patients from 2002–2007 (n = 955)
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structured care has been found previously to raise the
quality of diabetes care.11,17,18
Computerised knowledge management and organ-
isational interventions are becoming an essential part
of diabetes care.11,19 Integrated computerised health
information has been associated with better diabetes
care in the US Veterans Aﬀairs health care system,20
and computerised prompting has been found to im-
prove compliance to clinical practice guidelines.19 In
the UK, the national Quality Manager and Analysis
System was established to support payments since 2004
to general practitioner (GP) practices under the Quality
and Outcomes Framework in an eﬀort to inﬂuence
clinical behaviour and quality care.21 In many of these
systems, there is a requirement for expensive live data-
bases where GP practices submit clinical and non-
clinical data. In the present study, the HbA1c tool was
developed using existing laboratory data. The advan-
tage to this approach is that the regional health
authority is providing a means for GPs to use existing
data innovatively in order to provide the opportunity
to change clinical practice behaviour and improve
the quality of diabetes care. In an age of technology,
computer-generated reminder and recall systems may
prove to be an eﬃcient approach to diabetes manage-
ment, and based on the data obtained here (92%usage
rates) this approach would be popular and would be
frequently used by primary care physicians.
Limitations
There are a number of possible historical variables
that may have played a role in explaining the results
obtained here. It is possible that our data simply reﬂect
the trends observed over the past ten years. Increases in
glycaemic control and guideline adherence have been
found in other studies.22–24 Moreover, increased edu-
cational eﬀorts aimed at both physicians and people
with diabetes may also explain these trends. Future
studies will need to explore these ﬁndings in more
detail in order to verify whether speciﬁc characteristics
of patients, medical conditions and physicians inﬂu-
ence the eﬀectiveness of interventions based on com-
puter-generated laboratory data. Finally, it is also
possible that the high usage rates obtained reﬂect a
bias in the physicianswho responded to the survey: the
physicians who use the tracking tool may have been
more willing to respond to a survey concerning its use.
Conclusions
In this project, it was shown that routinely collected
laboratory data can be used both as the basis for an
information-based intervention and as a tool tomonitor
quality of diabetes care. These data can also provide an
eﬃcient and possibly economical means to address
health services research questions using large cross-
sectional and longitudinal data. The HbA1c Tracking
Tool is an economical option that can support patients
by providing them with supplementary information
to take control of their disease. Physicians can beneﬁt
from a tool that allows them to assess a patient’s long-
term glycaemic control andmonitor their own adher-
ence to existing clinical practice guidelines. Decision
makers can use HbA1c trend analysis to explore the
impact of population interventions aimed at improv-
ing diabetes care.
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